Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of ...

Similarly, Bi-Cygni Therapeutics employs its BiVictriX platform to enhance the efficacy and safety profiles of its bispecific antibodies. Debiopharm’s Multilink™ platform is another example ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

It is currently being tested in a Phase I clinical study (BBT001-001; NCT06808477) BBT002 is a novel half-life extended bispecific antibody designed as a "platform in a molecule" with broad ...

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...

Similarly, Bi-Cygni Therapeutics employs its BiVictriX platform to enhance the efficacy and safety profiles of its bispecific antibodies. Debiopharm's Multilink™ platform is another example that ...

BBT002 is a novel half-life extended bispecific antibody designed as a "platform in a molecule" with broad applications across respiratory, dermatology, and gastroenterology indications. Preclinical ...